NOVIAN Health Presents at the “2nd Annual Venture Connections: A Frost & Sullivan Executive Symposium”
San Francisco – March 12, 2008 – Eugene A. Bajorinas, Vice President of Operations
for NOVIAN Health, Inc., presented at the 2nd Annual Venture Connections: A Frost & Sullivan
Executive Symposium held in San Francisco, CA. The Venture Connections Symposium is a
uniquely interactive forum delivering opportunities for a critical mass of companies seeking
funding to showcase their business plans to the venture capital community, corporate venture
capital, and senior executives from the medical device and life sciences industries. Presenting
companies have successfully advanced through the Frost & Sullivan Investment Scorecard – a
comprehensive examination of key investment criteria. Mr. Bajorinas presented NOVIAN
Health’s business plan, highlighting the company’s accomplishments and the anticipated
commercialization of NovilaseTM, NOVIAN Health’s FDA-cleared treatment for fibroadenomas
(benign tumors) of the breast.
NOVIAN Health Inc., located in Chicago, is a privately held company with proprietary
technology for the treatment of tumors using Interstitial Laser Therapy (ILT). The company has
developed, tested, and patented a minimally-invasive procedure that uses ILT (controlled
heating) for the ablation of breast tumors as an alternative to the surgically invasive, traditional
“lumpectomy.” ILT offers significant advantages over surgical removal including minimal
scarring, quicker recovery times, and only requiring local anesthesia. NOVIAN Health received
its first FDA 510k clearance for fibroadenomas of the breast in 2007 and expects to offer its
technology at centers around the country. Approval for malignant tumors will also be sought.
